Business
Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
Company seeks partner to commercialize the technology TORONTO, July 9 /CNW/ - Microbix Biosystems...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"\n\n\n\nCompany seeks partner to commercialize the technology\n\n\nTORONTO, July 9 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) announced\ntoday that it has filed key patent applications based on its novel semen\nsexing discoveries and that it will now embark on the path to\ncommercialization of this exciting technology.\n\n\nMicrobix' recent discoveries should provide a more cost-effective\nplatform for semen sexing and significantly improve yields and quality of the\nsperm produced compared to the current commercial sexing technology.\n\n\nBoth are critical market factors that Microbix believes will allow the\ncompany to effectively penetrate and even expand the $3 billion Artificial\nInsemination (AI) market.\n\n\nSemen sexing is instrumental to the dairy industry due to the growing\ninternational demand for female offspring and the negligible value of dairy\nbull calves.\n\n\n"This market is attractive for its size and the absence of regulatory\nbarriers, and importantly, our technology offers a predictable pathway through\ndevelopment to market," said William J. Gastle, C.E.O.\n\n\n"Now that the intellectual property has been secured, we are focused on\nfinding a strategic partner(s) to help realize Microbix' Semen Sexing\nTechnology's (SST) significant commercial potential and we invite expressions\nof interest," said Mr. Gastle.\n\n\nMicrobix specializes in the development of biological technologies and\ncommercializing them through global partners. The Company has intellectual\nproperty in large market biotherapeutic drugs, vaccine technologies and animal\nreproduction technologies. Established in 1988, Microbix is headquartered in\nMississauga.\n\n\nThis press release contains forward-looking statements, which are subject\nto risks and uncertainties that could cause actual results to differ\nmaterially from those set forth in the forward-looking statements including\nthe risks associated with failure to develop and commercialize SST;\nnon-adoption of SST. These forward-looking statements represent the Company's\njudgment as of the date of this press release. The Company disclaims any\nintent or obligation to update these forward-looking statements.\n\n\n%SEDAR: 00004220E\n\n\n","length":2297,"tagName":"div"}]